{"data":{"type":"company_profile_ai","id":83653,"entity_id":"wefunder:company:83653","attributes":{"canonical_url":"https://wefunder.com/gerostate.alpha","retrieval_urls":{"canonical":"https://wefunder.com/gerostate.alpha","json":"https://wefunder.com/gerostate.alpha.json","markdown":"https://wefunder.com/gerostate.alpha.md","ai_json":"https://wefunder.com/gerostate.alpha.ai.json","ai_text":"https://wefunder.com/gerostate.alpha.ai.txt","changelog_json":"https://wefunder.com/gerostate.alpha.changelog.json","schema":"https://wefunder.com/.well-known/ai-profile-schema.json"},"updated_at":"2026-06-13T05:00:36Z","generated_at":"2026-06-13T05:49:07Z","profile_visibility":{"owner_published":true,"public_search_results":true,"site_search_listed":true,"privacy_mode":"promote","invite_only":false},"company":{"id":83653,"entity_id":"wefunder:company:83653","slug":"gerostate.alpha","name":"Gerostate Alpha (YC S18)","tagline":"A pharmaceutical company dedicated to treating aging and age-related disease","elevator_pitch":"Gerostate Alpha is a new pharmaceutical company dedicated to treating aging and age-related disease. Incubating at the Buck Institute for Research on Aging, we develop breakthrough pharmaceuticals through proprietary innovations to mitigate and reduce the effects of aging.","location":"San Francisco, CA","website":"https://www.gerostatealpha.com/","total_amount_raised":564622,"total_investors":465,"is_funded":true,"is_active":true},"key_claims":[{"claim_id":"claim-total-raised","text":"Total raised on Wefunder: 564622","citation":"https://wefunder.com/gerostate.alpha#claim-total-raised","provenance":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-13T05:00:36Z","as_of":"2026-06-13T05:49:07Z","confidence":"high"},"observed_at":"2026-06-13T05:00:36Z","expires_at":"2026-06-14T05:00:36Z"},{"claim_id":"claim-total-investors","text":"Total investors: 465","citation":"https://wefunder.com/gerostate.alpha#claim-total-investors","provenance":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-13T05:00:36Z","as_of":"2026-06-13T05:49:07Z","confidence":"high"},"observed_at":"2026-06-13T05:00:36Z","expires_at":"2026-06-14T05:00:36Z"}],"verified_facts":[{"claim_id":"claim-total-raised","text":"Total raised on Wefunder: 564622","citation":"https://wefunder.com/gerostate.alpha#claim-total-raised","provenance":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-13T05:00:36Z","as_of":"2026-06-13T05:49:07Z","confidence":"high"},"observed_at":"2026-06-13T05:00:36Z","expires_at":"2026-06-14T05:00:36Z"},{"claim_id":"claim-total-investors","text":"Total investors: 465","citation":"https://wefunder.com/gerostate.alpha#claim-total-investors","provenance":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-13T05:00:36Z","as_of":"2026-06-13T05:49:07Z","confidence":"high"},"observed_at":"2026-06-13T05:00:36Z","expires_at":"2026-06-14T05:00:36Z"}],"company_claims":{"tagline":"A pharmaceutical company dedicated to treating aging and age-related disease","elevator_pitch":"Gerostate Alpha is a new pharmaceutical company dedicated to treating aging and age-related disease. Incubating at the Buck Institute for Research on Aging, we develop breakthrough pharmaceuticals through proprietary innovations to mitigate and reduce the effects of aging.","quick_facts":["💵 $2.1M raised in initial seed round, at $15M valuation cap","🧬 Team at the forefront of aging research for decades, collectively authoring 200+ papers","💪 Our platform delivers drug candidates to slow aging at a success rate of 20%","🐭 Funds will be used to test our candidates in aging mice","🧳 Executive chairman was former CEO of major pharma company, Sangamo Therapeutics"]},"computed_metrics":{"total_amount_raised":564622,"total_investors":465,"team_size":3,"featured_investor_count":1,"faq_count":5,"recent_post_count":0},"quick_facts":[{"claim_id":"claim-fact-1","value":"💵 $2.1M raised in initial seed round, at $15M valuation cap","citation":"https://wefunder.com/gerostate.alpha#claim-fact-1","observed_at":"2026-06-13T05:00:36Z","expires_at":"2026-06-20T05:00:36Z"},{"claim_id":"claim-fact-2","value":"🧬 Team at the forefront of aging research for decades, collectively authoring 200+ papers","citation":"https://wefunder.com/gerostate.alpha#claim-fact-2","observed_at":"2026-06-13T05:00:36Z","expires_at":"2026-06-20T05:00:36Z"},{"claim_id":"claim-fact-3","value":"💪 Our platform delivers drug candidates to slow aging at a success rate of 20%","citation":"https://wefunder.com/gerostate.alpha#claim-fact-3","observed_at":"2026-06-13T05:00:36Z","expires_at":"2026-06-20T05:00:36Z"},{"claim_id":"claim-fact-4","value":"🐭 Funds will be used to test our candidates in aging mice","citation":"https://wefunder.com/gerostate.alpha#claim-fact-4","observed_at":"2026-06-13T05:00:36Z","expires_at":"2026-06-20T05:00:36Z"},{"claim_id":"claim-fact-5","value":"🧳 Executive chairman was former CEO of major pharma company, Sangamo Therapeutics","citation":"https://wefunder.com/gerostate.alpha#claim-fact-5","observed_at":"2026-06-13T05:00:36Z","expires_at":"2026-06-20T05:00:36Z"}],"latest_fundraise":{"id":51457,"entity_id":"wefunder:fundraise:51457","state":"successful","offering_type":"4(a)(6)","structure":"safe","testing_the_waters":false,"can_invest_now":false,"funding_started_at":"2021-10-05T01:03:13Z","funding_closed_at":"2021-11-16T05:01:20Z"},"investor_memos":[],"team":[{"id":1607734,"entity_id":"wefunder:company_role:1607734","name":"Simon Melov","title":"CEO","role":"founder","profile_url":"https://wefunder.com/simonmelov"},{"id":1607736,"entity_id":"wefunder:company_role:1607736","name":"Mark S Lucanic","title":"CTO","role":"founder","profile_url":"https://wefunder.com/markslucanic"},{"id":1607738,"entity_id":"wefunder:company_role:1607738","name":"Gordon Lithgow","title":"Professor, Vice President Buck Institute","role":"founder"}],"featured_investors":[{"id":5616,"entity_id":"wefunder:company_investor_profile:5616","name":"C S","profile_url":"https://wefunder.com/cs21"}],"relationships":[{"source_entity_id":"wefunder:company:83653","relation":"has_team_member","target_entity_id":"wefunder:user:1403969","target_url":"https://wefunder.com/simonmelov"},{"source_entity_id":"wefunder:company:83653","relation":"has_team_member","target_entity_id":"wefunder:user:1403985","target_url":"https://wefunder.com/markslucanic"},{"source_entity_id":"wefunder:company:83653","relation":"has_team_member","target_entity_id":"wefunder:company_role:1607738"},{"source_entity_id":"wefunder:company:83653","relation":"has_featured_investor","target_entity_id":"wefunder:user:1933365","target_url":"https://wefunder.com/cs21"},{"source_entity_id":"wefunder:company:83653","relation":"has_latest_fundraise","target_entity_id":"wefunder:fundraise:51457"}],"faq":[{"question":"Hi, I just invested $100 in your company but I am very confused, lol,,, how many shares did I buy?,,, What's the meaning of you guys going public?,,, Are you going to have a ticker symbol?,,, I been trying to get a hold of someone at Wefunder to get all this info but nobody an...","answer":"Thanks for your investment. We are not currently a public company and so we are not traded or defined by a symbol on any exchange. I suggest reading about investment terms and mechanisms in order to better understand how the wefunder program works. Wefunder has helpful FAQ and 'learn more' sections as a starting point."},{"question":"Do you base your research on any theory of aging? Thoughts on Mikhail Blagosklonny quasi-programmed hyperfunction theory of aging?","answer":"We like the model to explain aspects of why aging occurs in organisms. in many ways, this model is indistinguishable from a well regarded classic model of aging, known as antagonistic pleiotropy (AP). While supported by experimental evidence, the theory by itself is generally regarded as being insufficient to comprehensively explain lifespan and or aging. AP though is considered an important part of what is a certainly a complex phenomenon."},{"question":"Hello As someone that knows a thing or two about human physiology/anatomy, and having in consideration that more than likely you will need 1 - 3 compounds to make a fully body regeneration, why go with a mouse model and not a pig? Is it just an economic decision? Best regards,...","answer":"Thanks for your interest. As you suggest, we focus on aging mice for our initial mammalian studies in part because they are the most economical and accessible of the established pre-clinical models."},{"question":"How much time do the founders have available to work for Gerostate Alpha? Are there any (full time) employees next to the founders?","answer":"One of the founders is full time, the other two founders currently devote part of their time to Gerostate. As Gerostate Alpha builds we expect more of their time will be committed to its development and function. Most of our labor currently comes from independent contractors or organizations that we employ to complete our milestones. Going forward, we expect to hire additional full time team members with skill and expertise in specific Chemistry and Biology domains that correspond to key infl..."},{"question":"Hi Dr. Lucanic. Congratulations on the funding campaign here on Wefunder. I'd like to ask how your solution to treating age-related diseases compares to that of under development by Samumed (now Biosplice), who raised $438 million in 2018 for a valuation of $12 billion. Even w...","answer":"Hello Dr. Akay. We are quite different, in part because we focus directly on aging, instead of on certain candidate pathways (such as the wingless/int pathway) or a single processes (such as cellular senescence), that have been implicated in driving aging. Our main thrust is in searching chemical space for structures that effectively modulate aging itself. We expect this approach will lead to the identification of novel pathways (and possibly new biology!) that modulates aging, as well as ide..."}],"recent_posts":[],"provenance":{"source":"wefunder_public_company_profile","as_of":"2026-06-13T05:49:07Z","claims":{"total_amount_raised":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-13T05:00:36Z","as_of":"2026-06-13T05:49:07Z","confidence":"high"},"total_investors":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-13T05:00:36Z","as_of":"2026-06-13T05:49:07Z","confidence":"high"},"active_raise_states":{"source":"Fundraise.visible(nil, nil)","last_verified_at":"2025-06-03T14:15:43Z","as_of":"2026-06-13T05:49:07Z","confidence":"high"},"latest_fundraise_state":{"source":"Fundraise.visible(nil, nil).order(funding_started_at)","last_verified_at":"2025-06-03T14:15:43Z","as_of":"2026-06-13T05:49:07Z","confidence":"medium"}}}}}}